These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lychnopholide in Poly(d,l-Lactide)- Branquinho RT; de Mello CGC; Oliveira MT; Reis LES; Vieira PMA; Saúde-Guimarães DA; Mosqueira VCF; de Lana M Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988096 [TBL] [Abstract][Full Text] [Related]
4. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113 [TBL] [Abstract][Full Text] [Related]
5. Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review. Rev Inst Med Trop Sao Paulo; 2020; 62():e52err. PubMed ID: 32844906 [No Abstract] [Full Text] [Related]
6. An update on benznidazole for the treatment of patients with Chagas disease. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Lychnopholide Polymeric Nanocapsules after Oral and Intravenous Administration in Murine Experimental Chagas Disease. de Mello CG; Branquinho RT; Oliveira MT; Milagre MM; Saúde-Guimarães DA; Mosqueira VC; Lana Md Antimicrob Agents Chemother; 2016 Sep; 60(9):5215-22. PubMed ID: 27324760 [TBL] [Abstract][Full Text] [Related]
14. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034 [TBL] [Abstract][Full Text] [Related]
15. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164 [TBL] [Abstract][Full Text] [Related]
16. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon. Perin L; Fonseca KDS; de Carvalho TV; Carvalho LM; Madeira JV; Medeiros LDF; Molina I; Correa-Oliveira R; Carneiro CM; Vieira PMA Exp Parasitol; 2020 Mar; 210():107834. PubMed ID: 31978394 [TBL] [Abstract][Full Text] [Related]
17. Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease. Branquinho RT; Mosqueira VC; de Oliveira-Silva JC; Simões-Silva MR; Saúde-Guimarães DA; de Lana M Antimicrob Agents Chemother; 2014; 58(4):2067-75. PubMed ID: 24449777 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Cencig S; Coltel N; Truyens C; Carlier Y Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742 [TBL] [Abstract][Full Text] [Related]
19. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection. Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480 [TBL] [Abstract][Full Text] [Related]